Van Leth F, Martin D, Fisher M, Laplume H, Conway B, Robinson P, Wit FW, Lange JM; IAS Conference on HIV Pathogenesis and Treatment (2nd : 2003 : Paris, France).
Antivir Ther. 2003; 8 (Suppl.1): abstract no. 551.
International Antiviral Therapy Evaluation Center, Amsterdam, The Netherlands
BACKGROUND: The 2NN study is a multicentre randomized trial comparing efficacy and safety of first-line antiretroviral treatment containing nevirapine (NVP) and/or efavirenz (EFV). The present sub-study examines differences in the quality of life (QoL) during 48 weeks of follow-up. METHODS: Patients were treated with d4t+3TC plus either NVP once daily, NVP twice daily, EFV or NVP+EFV. The NVP-only arms were combined because there were no differences in QoL changes. QoL was assessed by the MOS-HIV questionnaire, which captures physical and mental well being in 11 subscales and two summary measures [physical health score (PHS) and mental health score (MHS)]. The scales range from 0 (bad) to 100 (good). Patients in Thailand (n=210), Poland (n=22) and Greece (n=8) were excluded, since no validated version of the questionnaire existed for these languages. The summary measures and subscales were evaluated for change in the QoL score between baseline and week 48 by ANOVA. RESULTS: Of the 1216 patients, 976 were eligible for the present study. Of these, 471 (48%) had QoL scores available at both baseline and week 48. There were no differences between the arms in changes in QoL for any of the subscale or summary scores. The increase in PHS for NVP was 3.9, for EFV 3.4 and for NVP+EFV 2.9 (P=0.712). For MHS, the increases were 6.1, 7.0 and 3.9, respectively (P=0.098). Baseline plasma HIV-1 concentration (pVL) of >100000 copies/ml was significantly associated with improvements in PHS and MHS, while baseline CD4 count or disease stage were not. CONCLUSIONS: Although treatment of naive patients with NVP or EFV combination regimens resulted in significant improvements in pVL and CD4 counts, these changes may not be reflected by significant improvements in QoL, for periods up to 48 weeks. However, patients with baseline pVL >100000 copies/ml significantly increase their QoL, regardless of the treatment received.
Publication Types:
Keywords:
- Antiretroviral Therapy, Highly Active
- CD4 Lymphocyte Count
- Drug Therapy, Combination
- Greece
- HIV Infections
- HIV Seropositivity
- HIV-1
- Humans
- Lamivudine
- Nevirapine
- Oxazines
- Poland
- Stavudine
- Thailand
- drug therapy
- efavirenz
- therapy
Other ID:
UI: 102262833
From Meeting Abstracts